779198-52-6

Upstream product

• 10272-06-7 3-chloro-5-methoxyaniline 
• 174913-12-3 1-bromo-3-chloro-5-methoxybenzene 
• 779186-94-6 dimethyl-thiocarbamic acid O-(3-chloro-5-methoxy-phenyl) ester 

Downstream Products

• 779198-59-3 methyl 4-((3-chloro-5-methoxyphenyl)sulfanyl)-3-oxobutanoate 
• 1127948-06-4 1-chloro-3-(2,2-diethoxy-ethylsulfanyl)-5-methoxy-benzene 
• 779202-69-6 {4-Chloro-6-[5-(4-trifluoromethyl-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid methyl ester 
• 779198-80-0 {4-Chloro-6-[5-(4-chloro-phenyl)-isoxazol-3-ylmethoxy]-benzo[b]thiophen-3-yl}-acetic acid methyl ester 
• 945773-93-3 C₂₃H₁₇ClF₃NO₃S₂ 

Relevant academic research and scientific papers

Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue

Analogues of the natural product cyclosporine A (CsA) were developed and assessed as antivirals against infection of hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). An analogue termed 27A exhibits potent inhibition of HBV/HDV infection by specifically blocking viral engagement to its cellular receptor NTCP, while it lacks immunosuppressive activity found in natural CsA. Intraperitoneal injection or oral intake of 27A protects HDV-susceptible mouse model from HDV infection. 27A serves as a promising lead for the development of novel anti-HDV/HBV agents.

GHRELIN O-ACYLTRANSFERASE INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment

NOVEL FUNGICIDES

Compounds of the general formula (I), wherein the substituents are as defined in claim 1, are useful as fungicides.

Compounds that modulate PPAR activity and methods of preparation

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.